Until the recent FDA approval of Syfovre, there was no treatment to address the symptoms of AMD, according to a May 10 press release.
Syfovre slows degeneration of the retinal cells and provides patients with visual function for many more months or years.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
